What’s more, researchers suggested that targeting cannabinoid (CB) receptors/modulating the degree or activity of endocannabinoids in tissue is beneficial to decrease insulin/leptin resistance in diabetes and mitigate the myocardial damage during I/R phase [125, 126]. This evidence concerns the gene INS and diabetes mellitus.